Ignite Creation Date:
2024-05-06 @ 8:10 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06282120
Status:
RECRUITING
Last Update Posted:
2024-02-28
First Post:
2024-02-21
Brief Title:
Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FULV Immunotherapy in First-line Gemsitabine Immunoprogressive Patients With Metastatic Biliary Tract Cancer
Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Organization:
Tianjin Medical University Cancer Institute and Hospital
Organization Data
Organization:
Tianjin Medical University Cancer Institute and Hospital
Class:
OTHER
Study ID:
CSPC-DNY-BTC
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| CSPC Ouyi Pharmaceutical Co Ltd | INDUSTRY |